Center on Health Equity & Access
Clinical
Health Care Cost
Health Care Delivery
Insurance
Policy
Technology
Value-Based Care

Biosimilars Cardiorenalmetabolic Dermatology Gastroenterology Hematology Hepatology Immunology Infectious Disease Mental Health Neurology Obesity Oncology Ophthalmology Pulmonology Rare Disease Respiratory Rheumatology Women's Health

Free In-Person Regional Events Focused on Oncology and Population Health

Biosimilars Center on Health Equity & Access Digital Health Formulary Gene Therapy Guidelines Health Care Administration Health Care Cost Health Care Delivery Insurance Policy Population Health Product Approvals and Launches Technology Value-Based Care

All Coverage Event Coverage Interviews News

AJMC Journals Anniversary Author Forms Authors Nominate a Rising Leader Submit a Manuscript

Megan McNicol, PharmD, BCACP

home / authors / megan-mcnicol-pharmd-bcacp

Articles

AJMC original research clinical

The Biosimilar Shift: Trending Infliximab Biosimilar Utilization and Associated Cost Savings for Commercial Insurance

October 14th 2025

Infliximab biosimilars created price competition causing insurance claims costs for infliximab originator and infliximab biosimilars to decrease, generating significant savings to the health care system.

Editorial Boards

Do Not Sell My Information

Terms & Conditions

Contact Info

2 Commerce Drive
Cranbury, NJ 08512

© 2025 MJH Life Sciences
AJMC®
All rights reserved.